Amgen Director shares strategies to maximise reimbursement success

LONDON, ENGLAND, December 22, 2010 (Press-News.org) Fletcher said: "The Health Technology Assessment dossier is really the single opportunity that people have to convince payers of the value of a new product coming through. So in order to do that effectively, the more that that data is available for that dossier, and it's reported in the right way, means that you're going to have your best chance. And it should be as comprehensive and as transparent and as unbiased as possible."

Fletcher also spoke of Biopharma's increasing attention to focus on products for sub-populations. According to her, a lot of work is beginning to focus around sub-populations of interest. In particular, heath authorities are looking to see "do we have any sub-populations, which are more cost effective?". ''So often we need to make sure that we come up, we have enough data in the literature to look at sub-populations not of our own drugs, but also of our comparators."

To listen to the full podcast, please visit HTA online resource library: http://www.htaforum.com/Event.aspx?id=440802.

The podcast was recorded in correlation with Chrissie's session 'Clinical Design, Analysis and Reporting' strategies to maximise reimbursement success, that will be part of the upcoming Health Technology Conference, taking place in 06-07 April 2011 in London. She will discuss optimising the design of clinical trials to meet HTA need, analysing best-practice approaches for synthesising clinical evidence to demonstrate product value as well understanding how best to report and interpret outcomes for reimbursement dossiers.

If you want to find out more about Chrissie Fletcher's session, please visit http://www.htaforum.com, call 44 (0) 207 368 9421 or email enquire@iqpc.co.uk